[Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
From December 1989 to September 1992, nine patients with impotence were instructed to perform intracavernous self-injection of vasoactive drugs. At first 40 mg of papaverine hydrochloride was used in all patients and the response on erection was evaluated. If the response did not show sufficiently functional erection, a mixture of 40 mg of papaverine hydrochloride and 1 mg of phentolamine mesylate or 20 mg of prostaglandin E1 was reinjected. Eight patients had achieved full erections and vaginal penetrations without noteworthy complications during the follow-up period. Out of eight patients, three patients were able to ejaculate and one patient showed recovery of erection. No major side effects were seen. In conclusion, intracavernous self-injection is a useful modality for impotence.
Hayashi
S
S
Department of Urology, Izumi Municipal Hospital.
Iwai
Y
Y
Yasumoto
R
R
Matsuda
J
J
Kawano
M
M
Omachi
T
T
Kono
T
T
Yamamoto
S
S
Sakakura
T
T
Minami
H
H
D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000008:administration & dosage*; D010410:Penile Erection / Q000187:drug effects; D010413:Penis; D010646:Phentolamine / Q000008:administration & dosage / Q000031:analogs & derivatives; D012646:Self Administration
D010208:Papaverine; D000527:Alprostadil; D010646:Phentolamine